We’re tackling the world’s toughest health challenges
Johnson & Johnson Innovative Medicine is leading where medicine is going. Patients inform and inspire our science-based innovations, which continue to change and save lives. With rigorous science and compassion, we confidently address the most complex diseases of our time and unlock the medicines of tomorrow. Healthcare areas include: Oncology, Immunology, Neuroscience and Cardiopulmonary.
Johnson & Johnson MedTech innovates at the intersection of biology and technology. With a focus on treating with pinpoint precision in the hardest-to-reach parts of the body, restoring anatomy and reimagining healing, our portfolio of smarter, less invasive, more personalized treatments is addressing the most complex health challenges. Healthcare areas include: Cardiovascular, Orthopaedics, Surgery and Vision.
Innovating in healthcare
-
What you need to know about Johnson & Johnson’s second-quarter 2026 earnings report
Check out this infographic breakdown of the company’s second-quarter performance, with highlights from its Innovative Medicine and MedTech businesses. -
“We are in a golden age of cataract surgery”
Once considered a straightforward procedure to restore cloudy vision, cataract surgery has evolved into one of the most technologically advanced—and personalized—operations in modern medicine. Learn how Johnson & Johnson’s 25-year history of innovation is helping eye surgeons meet the moment. -
How the Polyphonic™ AI Fund for Surgery QuickFire Challenge awardees are aiming to empower surgeons
Johnson & Johnson launched this competition with one goal: to accelerate the development of next-generation surgical technologies. Meet this year’s three awardees and learn about their innovations.
-
3 nurse practitioners who are filling critical gaps in healthcare
From using cutting-edge technology to address mental health issues to launching an urban clinic that helps treat substance-abuse disorders and taking an innovative approach to deliver rural medical care, learn how Johnson & Johnson is helping support a new generation of providers. -
Striving for a cure for multiple myeloma: What HCPs need to know
Jordan Schecter, M.D., leader of Johnson & Johnson’s end-to-end development strategy for multiple myeloma, shares insight on the evolving treatment landscape of this rare blood cancer.
Learn more about how we are innovating
“Reimagining what life with schizophrenia could look like”
Johnson & Johnson’s Leonardo Diaz, M.D., addresses common misconceptions about schizophrenia, the critical importance of preventing relapse and why there’s so much optimism about treatments.
Giving the gift of sight
In Kenya, around 1.5 million people—including children—contend with visual impairment or blindness. Sight For Kids, Johnson & Johnson’s global eye-care partnership, is devoted to changing these stats, one vision screening at a time.
Getting in front of cancer
Every year, roughly 2 million people in the U.S. are newly diagnosed with cancer. But new scientific breakthroughs—including ones made at Johnson & Johnson—have dramatically changed the prognosis of many of these patients.
5 things we now know about atrial fibrillation
More than 50 million people worldwide are affected by this common type of heart arrhythmia. Learn the facts behind this heart condition, plus one patient’s diagnosis story.